tbuckley/cabot-search huggingface dataset:
SOCIETY PROCEEDINGS.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PHARMACOPEIA AND THE PHYSICIAN.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease—Reply
Authors: Eric A. Macklin, Alberto Ascherio, Michael A. Schwarzschild
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dermatology
Authors: J. S. Dover
Journal: JAMA (1995)

Calcipotriene ointment, a synthetic structural analogue of 1,25-dihidroxycholecalciferol, has recently been approved for the treatment of moderate plaque psoriasis by the Food and Drug Administration. Ten years ago, 1,25-dihidroxycholecalciferol was noted to inhibit the proliferation of psoriatic fibroblasts in culture.<sup>1</sup>This finding, along with the fact that a patient being treated with 1α-hydroxyvitamin D<sub>3</sub>for osteoporosis noted marked improvement in her psoriasis, stimulated investigators to assess the effect of a variety of analogues of vitamin D on psoriasis. Calcipotriene (calcipotriol) is recognized with equal affinity by the 1,25-dihidroxycholecalciferol receptor but has 100 times less effect on calcium metabolism than does vitamin D.<sup>2</sup>The drug is believed to exert its therapeutic effect through inhibition of keratinocyte proliferation and increasing terminal differentiation of keratinocytes. Placebo-controlled, randomized, double-blind trials have demonstrated the effectiveness (80% of patients treated for 6 months demonstrate at least moderate improvement), rapid activity, and safety of
Atherosclerosis, a progressive disease
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
One-year results after multivessel stenting in diabetic vs. Non diabetic patients Alexander Abizaid, George Dangas, Roxana Mehran, Yoshio Kobayashi, Andrea S. Abizaid, Gary S. Mintz, Milena G. Adamian, Rajshekar Narasimaiah, Cristian Cioara, Augusto D. Pichard, Gregg W. Stone, Martin B. Leon. Cardiovascular Research Foundation, New York, NY, Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Early Detection in Childhood Lead Exposure Relies on Timely Testing
Authors: Brian T. Whitley, Dana Squires, Ann Maxwell
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Induction of tumor necrosis factor-alpha and left ventricular dysfunction in the recipient heart following myocardial infarction in the remote donor heart in a heterotopic syngenic transplant model: Evidence of a novel unique cytokine intranet signaling pathway Hiroshi Nakamura, Gordon Moe, George Naik, Josef Penninger, Fayez Dawood, Jianxin Ren, Peter Liu. Heart &amp; Stroke/Richard Lewar Centre of Excellence, Univ of Toronto, Toronto, ON, Canada
Journal: Journal of the American College of Cardiology (2001)
Structural insights into the catalytic and inhibitory mechanisms of the flavin transferase FmnB in <i>Listeria monocytogenes</i>
Authors: Yanhui Zheng, Weizhu Yan, Chao Dou, Dan Zhou, Yunying Chen, Ying Jin, Lulu Yang, Xiaotao Zeng, Wei Cheng
Journal: MedComm (2022)

Listeria monocytogenes, a food-borne Gram-positive pathogen, often causes diseases such as gastroenteritis, bacterial sepsis, and meningitis. Newly discovered extracellular electron transfer (EET) from L. monocytogenes plays critical roles in the generation of redox molecules as electron carriers in bacteria. A Mg2+-dependent protein flavin mononucleotide (FMN) transferase (FmnB; UniProt: LMRG_02181) in EET is responsible for the transfer of electrons from intracellular to extracellular by hydrolyzing cofactor flavin adenine dinucleotide (FAD) and transferring FMN. FmnB homologs have been investigated in Gram-negative bacteria but have been less well studied in Gram-positive bacteria. In particular, the catalytic and inhibitory mechanisms of FmnB homologs remain elusive. Here, we report a series of crystal structures of apo-FmnB and FmnB complexed with substrate FAD, three inhibitors AMP, ADP, and ATP, revealing the unusual catalytic triad center (Asp301-Ser257-His273) of FmnB. The three inhibitors indeed inhibited the activity of FmnB in varying degrees by occupying the binding site of the FAD substrate. The key residue Arg262 of FmnB was profoundly affected by ADP but not AMP or ATP. Overall, our studies not only provide insights into the promiscuous ligand recognition behavior of FmnB but also shed light on its catalytic and inhibitory mechanisms.
Specialty Abstracts
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation
Authors: Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara
Journal: Hepatology (2022)

Background and Aims: Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets. Approach and Results: We performed a Sleeping Beauty transposon‐based in vivo insertional mutagenesis screen in liver‐specific Pten ‐deficient mice and identified TNF receptor–related factor 3 ( Traf3 ) as the most significantly mutated gene in murine ICCs in a loss‐of‐function manner. Liver‐specific Traf3 deletion caused marked cholangiocyte overgrowth and spontaneous development of ICC in Pten knockout and Kras G12D mutant mice. Hepatocyte‐specific, but not cholangiocyte‐specific, Traf3 ‐deficient and Pten ‐deficient mice recapitulated these phenotypes. Lineage tracing and single‐cell RNA sequencing suggested that these ICCs were derived from hepatocytes through transdifferentiation. TRAF3 and PTEN inhibition induced a transdifferentiation‐like phenotype of hepatocyte‐lineage cells into proliferative cholangiocytes through NF‐κB‐inducing kinase (NIK) up‐regulation in vitro. Intrahepatic NIK levels were elevated in liver‐specific Traf3 ‐deficient and Pten ‐deficient mice, and NIK inhibition alleviated cholangiocyte overgrowth. In human ICCs, we identified an inverse correlation between TRAF3 and NIK expression, with low TRAF3 or high NIK expression associated with poor prognosis. Finally, we showed that NIK inhibition by a small molecule inhibitor or gene silencing suppressed the growth of multiple human ICC cells in vitro and ICC xenografts in vivo. Conclusions: TRAF3 inactivation promotes ICC development through NIK‐mediated hepatocyte transdifferentiation. The oncogenic TRAF3–NIK axis may be a potential therapeutic target for ICC.
Responses to immunotherapy in hepatocellular carcinoma patients with nonalcoholic steatohepatitis cirrhosis.
Authors: Jeremy Chang, Joseph S Ryan, Veeral Ajmera, Stephanie Ting, Pablo Tamayo, Adam Burgoyne
Journal: Journal of Clinical Oncology (2022)

389 Background: Hepatocellular carcinoma (HCC) is the most rapidly growing cause of cancer-related mortality in the United States. Recent preclinical studies suggest that immunotherapy agents targeted at programmed cell death protein 1 (PD-1) do not lead to tumor regression in HCC with underlying nonalcoholic steatohepatitis (NASH). However, further clinical studies are needed to clarify the impact of immunotherapy on patients with NASH-related HCC. Methods: This was a single center, retrospective study analyzing the best responses to immunotherapy in patients with HCC and underlying cirrhosis due to NASH. Patients were divided into 2 groups: those with HCC related to NASH cirrhosis and those with HCC without NASH cirrhosis. All patients received immunotherapy, either as a single agent or in combination with other cancer-directed therapy, with response assessments conducted during their treatment courses. Results: A total of 79 patients were included in this study. There were 15 patients in the NASH cirrhosis-related HCC group and 64 patients in the HCC group without NASH cirrhosis. When analyzing the best disease responses to immunotherapy, 7 patients (46.7%) with HCC and NASH cirrhosis were found to have disease progression as their best responses compared to 7 patients (10.9%) who had HCC without NASH cirrhosis (risk ratio 4.27, p = 0.004). In addition, for the group without NASH cirrhosis, 57 patients (89.1%) experienced disease control (stable disease, partial response, or complete response) from immunotherapy versus 8 patients (53.3%) in the NASH cirrhosis-related HCC group (risk ratio 1.67, p = 0.004). There were no notable differences in patient age, gender, or immunotherapy agents received between the two groups, but there was a significantly greater proportion of patients of Hispanic ethnicity in the HCC group with NASH cirrhosis (p = 0.006, full patient characteristics listed in the table). However, when looking at all individuals in the study, patients of Hispanic ethnicity were not found to have a significantly higher risk of disease progression compared to non-Hispanic patients (p = 0.07). Conclusions: There were significantly higher rates of disease progression as the best response to immunotherapy in patients with HCC and NASH cirrhosis compared to those without NASH cirrhosis. With the expanded use of immunotherapy in HCC patients, further prospective studies are needed to clarify the impact of underlying liver disease etiology on immunotherapy response.[Table: see text]
Leaflet separation and interleaflet shearing during acute ischemic mitral regurgitation David T. M. Lai, Tomasz A. Timek, Paul Dagum, Sidney Lo, Truls Myrmel, Frederick A. Tibayan, David Liang, George T. Daughters, II, Neil B. Ingels, Jr., D. C. Miller. Stanford University School of Medicine, Stanford, CA, Research Institute of the Palo Alto Medical Foundation, Palo Alto, CA
Journal: Journal of the American College of Cardiology (2001)
<i>HMOX1</i> and Acute Kidney Injury in Sickle Cell Anemia
Authors: Santosh L. Saraf, Maya Viner, Ariel Rischall, Binal Shah, Xu Zhang, Jin Han, Michel Gowhari, Shivi Jain, Robert E. Molokie, Roberto F. Machado, James P. Lash, Victor R. Gordeuk
Journal: Blood (2017)
Designing and scaling up integrated youth mental health care
Authors: Patrick D. McGorry, Cristina Mei, Andrew Chanen, Craig Hodges, Mario Alvarez‐Jimenez, Eóin Killackey
Journal: World Psychiatry (2022)

Mental ill‐health represents the main threat to the health, survival and future potential of young people around the world. There are indications that this is a rising tide of vulnerability and need for care, a trend that has been augmented by the COVID‐19 pandemic. It represents a global public health crisis, which not only demands a deep and sophisticated understanding of possible targets for prevention, but also urgent reform and investment in the provision of developmentally appropriate clinical care. Despite having the greatest level of need, and potential to benefit, adolescents and emerging adults have the worst access to timely and quality mental health care. How is this global crisis to be addressed? Since the start of the century, a range of co‐designed youth mental health strategies and innovations have emerged. These range from digital platforms, through to new models of primary care to new services for potentially severe mental illness, which must be locally adapted according to the availability of resources, workforce, cultural factors and health financing patterns. The fulcrum of this progress is the advent of broad‐spectrum, integrated primary youth mental health care services. They represent a blueprint and beach‐head for an overdue global system reform. While resources will vary across settings, the mental health needs of young people are largely universal, and underpin a set of fundamental principles and design features. These include establishing an accessible, “soft entry” youth primary care platform with digital support, where young people are valued and essential partners in the design, operation, management and evaluation of the service. Global progress achieved to date in implementing integrated youth mental health care has highlighted that these services are being accessed by young people with genuine and substantial mental health needs, that they are benefiting from them, and that both these young people and their families are highly satisfied with the services they receive. However, we are still at base camp and these primary care platforms need to be scaled up across the globe, complemented by prevention, digital platforms and, crucially, more specialized care for complex and persistent conditions, aligned to this transitional age range (from approximately 12 to 25 years). The rising tide of mental ill‐health in young people globally demands that this focus be elevated to a top priority in global health.
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy
Authors: Yan Li, Chen Yang, Zhicheng Liu, Shangce Du, Susan Can, Hailin Zhang, Linmeng Zhang, Xiaowen Huang, Zhenyu Xiao, Xiaobo Li, Jingyuan Fang, Wenxin Qin, Chong Sun, Cun Wang, Jun Chen, Huimin Chen
Journal: Molecular Cancer (2022)

In recent years, the application of functional genetic immuno-oncology screens has showcased the striking ability to identify potential regulators engaged in tumor-immune interactions. Although these screens have yielded substantial data, few studies have attempted to systematically aggregate and analyze them.In this study, a comprehensive data collection of tumor immunity-associated functional screens was performed. Large-scale genomic data sets were exploited to conduct integrative analyses.We identified 105 regulator genes that could mediate resistance or sensitivity to immune cell-induced tumor elimination. Further analysis identified MON2 as a novel immune-oncology target with considerable therapeutic potential. In addition, based on the 105 genes, a signature named CTIS (CRISPR screening-based tumor-intrinsic immune score) for predicting response to immune checkpoint blockade (ICB) and several immunomodulatory agents with the potential to augment the efficacy of ICB were also determined.Overall, our findings provide insights into immune oncology and open up novel opportunities for improving the efficacy of current immunotherapy agents.
Effect of diabetes mellitus on coronary collateral circulation: Assessment by pressure-derived fractional collateral blood flow Koichi Tamita, Takashi Akasaka, Tsutomu Takagi, Atsushi Yamamuro, Kazuaki Tanabe, Kunihiko Nagai, Tomoko Tani, Kenji Yamabe, Minako Katayama, Shin Mizoguchi, Shigefumi Morioka. Kobe General Hospital, Kobe, Japan, Kawasaki Medical School, Kurashiki, Japan
Journal: Journal of the American College of Cardiology (2001)
Regulation of 3D Printing at Health Care Facilities
Authors: Rita Rubin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal